27 / 58
27
Miguel Ángel López Zúñiga
Agentes de acción directa y hepatitis C
Tabla 5. RVS según tratamiento antiVHC, CoinfecciónVIH y genotipo
SOF: Sofosbuvir; SIM: Simeprevir: DCV: Daclatasvir; RBV: Ribavirina; LPV: Ledipasvir; PRV: Paritaprevir; OBV: Ombitasvir; DSV: Dasabuvir, rit:
Ritonavir;IPeg: Interferon Pegilado
* En esta tabla no quedan reflejados aquellos paciente que, a pesar de haber tenido tratamiento y haber obtenido RVS, no se obtuvo genotipo
del VHC.
COINFECTADOVIH
TRATAMIENTO ANTI-VHC
RVS
TOTAL
NO
SI
1A
NO
OMB+ PAR/RITO +DAS
0
5 (100%)
5
SOF+LED
0
3 (100%)
3
DCV+SOF
1 (50%)
1 (50%)
2
SOF + SIM
0
3 (100%)
3
Total
1 (7,69%)
12 (92,3%)
13
SI
OMB+ PAR/RITO +DAS
0
8 (100%)
8
SOF+ LED
0
9 (100%)
9
DCV+SOF
0
4 (100%)
4
SOF + SIM
0
5 (100%)
5
Total
0
27 (100%)
27
1B
NO
OMB+ PAR/RITO +DAS
0
10 (100%)
10
SOF+ LED
0
3 (100%)
3
DCV+SOF
0
2 (100%)
2
DCV + SIM
0
2 (100%)
2
SOF + SIM
0
2 (100%)
2
Total
0
19 (100%)
19
SI
OMB+ PAR/RITO +DAS
1 (14,3%)
6 (85,7%)
7
SOF+ LED
0
4 (100%)
4
DCV + SIM
0
1 (100%)
1
SOF + SIM
0
2 (100%)
2
SIM + RBV + IPeg
1 (50%)
1 (50%)
2
Total
2 (12,5%)
14 (87,5%)
16
1 (SIN
SUBTIPAR)
NO
OMB+ PAR/RITO +DAS
0
1 (100%)
1
DCV+SOF
0
2 (100%)
2
Total
0
3 (100%)
3
SI
OMB+ PAR/RITO +DAS
0
2 (100%)
2
SOF+ LED
0
1 (100%)
1
SOF + SIM
0
1 (100%)
1
Total
0
4 (100%)
4
2
NO
SOF + RBV
0
3 (100%)
3
DCV + SOF
0
1 (100%)
1
Total
0
4 (100%)
4
SI
SOF + RBV
1 (33%)
2 (66%)
3
Total
1 (33%)
2 (66%)
3
3
NO
DCV+SOF
2 (22,2%)
7 (77,8%)
9
Total
2 (22,2%)
7 (77,8%)
9
SI
DCV+SOF
0
14 (100%)
14
SOF + RBV
1 (100%)
0
0
Total
1 (6,7%)
14 (93,3%)
15
4
NO
OMB+ PAR/RITO
0
2 (100%)
2
DCV+SOF
0
3 (100%)
3
SOF+ LED
0
1 (100%)
1
Total
0
6 (100%)
6
SI
OMB+ PAR/RITO
1 (10%)
9 (90%)
10
SOF+ LED
1 (14,3%)
6 (85,7%)
7
DCV+SOF
0
3 (100%)
3
SOF + SIM
0
1 (100%)
1
Total
2 (9,5%)
19 (90,5%)
21